126 related articles for article (PubMed ID: 20140299)
1. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease.
Zhang T; Wang L; Xiong X; Mao Z; Wang L; Mei C
Biol Res; 2009; 42(4):437-44. PubMed ID: 20140299
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat.
Jolicoeur EM; Qi S; Xu D; Dumont L; Daloze P; Chen H
Transplantation; 2003 Jan; 75(1):54-9. PubMed ID: 12544871
[TBL] [Abstract][Full Text] [Related]
4. Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).
Zafar I; Belibi FA; He Z; Edelstein CL
Nephrol Dial Transplant; 2009 Aug; 24(8):2349-53. PubMed ID: 19321761
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat.
Vu MD; Qi S; Xu D; Wu J; Peng J; Daloze P; Sehgal S; Leduc B; Chen H
Transplantation; 1998 Dec; 66(12):1575-80. PubMed ID: 9884242
[TBL] [Abstract][Full Text] [Related]
7. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease.
Wu M; Wahl PR; Le Hir M; Wackerle-Men Y; Wuthrich RP; Serra AL
Kidney Blood Press Res; 2007; 30(4):253-9. PubMed ID: 17596700
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats.
Romero F; Rodríguez-Iturbe B; Parra G; González L; Herrera-Acosta J; Tapia E
Kidney Int; 1999 Mar; 55(3):945-55. PubMed ID: 10027931
[TBL] [Abstract][Full Text] [Related]
9. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
10. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.
Tao Y; Kim J; Faubel S; Wu JC; Falk SA; Schrier RW; Edelstein CL
Proc Natl Acad Sci U S A; 2005 May; 102(19):6954-9. PubMed ID: 15863619
[TBL] [Abstract][Full Text] [Related]
11. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
[TBL] [Abstract][Full Text] [Related]
14. The effect of paclitaxel on the progression of polycystic kidney disease in rodents.
Martinez JR; Cowley BD; Gattone VH; Nagao S; Yamaguchi T; Kaneta S; Takahashi H; Grantham JJ
Am J Kidney Dis; 1997 Mar; 29(3):435-44. PubMed ID: 9041221
[TBL] [Abstract][Full Text] [Related]
15. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
Rodriguez D; Kapoor S; Edenhofer I; Segerer S; Riwanto M; Kipar A; Yang M; Mei C; Wüthrich RP
Kidney Blood Press Res; 2015; 40(6):638-47. PubMed ID: 26698317
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
Yang CW; Ahn HJ; Kim WY; Li C; Kim HW; Choi BS; Cha JH; Kim YS; Kim J; Bang BK
Kidney Int; 2002 Jul; 62(1):20-30. PubMed ID: 12081560
[TBL] [Abstract][Full Text] [Related]
18. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs.
Renders L; Steinbach R; Valerius T; Schöcklmann HO; Kunzendorf U
Kidney Blood Press Res; 2004; 27(3):181-5. PubMed ID: 15256815
[TBL] [Abstract][Full Text] [Related]
19. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
20. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
